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Antibody-mediated neutralizationosquito-borne ﬂavivirus responsible for 50 to 100 million human infections each
year, highlighting the need for a safe and effective vaccine. In this study, we describe the production of
pseudoinfectious DENV reporter virus particles (RVPs) using two different genetic complementation
approaches, including the creation of cell lines that release reporter viruses in an inducible fashion. In
contrast to studies with West Nile virus (WNV), production of infectious DENV RVPs was temperature-
dependent; the yield of infectious DENV RVPs at 37 °C is signiﬁcantly reduced in comparison to experiments
conducted at lower temperatures or with WNV. This reﬂects both a signiﬁcant reduction in the rate of
infectious DENV RVP release over time, and the more rapid decay of infectious DENV RVPs at 37 °C.
Optimized production approaches allow the production of DENV RVPs with titers suitable for the study of
DENV entry, assembly, and the analysis of the humoral immune response of infected and vaccinated
individuals.
© 2008 Published by Elsevier Inc.IntroductionDengue virus (DENV) is a mosquito-borne member of the Flavi-
virus genus that has a signiﬁcant impact on public health throughout
the tropics. Roughly 50–100 million individuals are infected with
DENV each year, with a signiﬁcant fraction of these cases involving
children (Gubler and Meltzer, 1999; Mackenzie et al., 2004; WHO,
1997). Clinical manifestations of DENV infection range from an acute
febrile illness to a potentially fatal syndrome characterized by plasma
leakage and shock (dengue shock syndrome; DSS) (Gubler et al.,
2007). Four antigenically related serotypes of DENV circulate in
nature. Prospective clinical studies indicate that the sequential
infection by two different serotypes of DENV is associated with a
more severe clinical outcome (Alvarez et al., 2006; Endy et al., 2004;
Stephens et al., 2002; Vaughn et al., 2000). DENV has spread
signiﬁcantly during the past thirty years and multiple serotypes of
virus are now simultaneously endemic in many parts of the world,
contributing to the dramatic rise in the number of severe cases
reported each year (Mackenzie et al., 2004). Factors that contribute to
the clinical manifestations associated with secondary DENV infections
are not completely understood (Halstead, 2003; Mongkolsapaya et al.,
2003; Rothman, 2004). However, the potential for pre-existing DENV
antibody to exacerbate disease following secondary infection with a
heterologous DENV serotype complicates the development of a safe).
lsevier Inc.and effective vaccine, and highlights the importance of understanding
the breadth, speciﬁcity, and durability of the humoral immune
response (Monath, 2007; Whitehead et al., 2007).
Pseudoinfectious virions that deliver reporter genes into cells have
been employed as a tool for the study of many viral systems, including
ﬂaviviruses. First developed to study the Kunjin strain of West Nile
virus (WNV) (Khromykh et al., 1998b), several related genetic
complementation strategies for ﬂaviviruses have now been character-
ized (Fayzulin et al., 2006; Gehrke et al., 2003; Harvey et al., 2004;
Jones et al., 2005; Khromykh et al., 1998a, 1998b; Lai et al., 2008;
Pierson et al., 2005; Scholle et al., 2004; Varnavski et al., 2000; Yoshii
et al., 2005). The backbone of these approaches are modiﬁed forms of
the ﬂavivirus genome, called replicons, inwhich the genes that encode
the structural proteins of the virus (capsid (C), pre-membrane (prM),
and envelope (E)) have been replaced with a reporter gene (Gehrke et
al., 2003; Hayasaka et al., 2004; Khromykh and Westaway, 1997;
Molenkamp et al., 2003; Pang et al., 2001; Shi et al., 2002). These self-
replicating sub-genomic replicons can then be packaged into
pseudoinfectious virions by genetic trans-complementation with
genes encoding the structural proteins. Using these approaches,
reporter virus particles (RVPs) of several different ﬂaviviruses have
been employed in studies of different aspects of the ﬂavivirus life cycle
in vitro and in vivo (Davis et al., 2006a, 2006b; Goto et al., 2005;
Khromykh and Westaway, 1997; Scholle et al., 2004; Whitby et al.,
2005; Yoshii et al., 2008).
We have developed quantitative and high-throughput methods to
study the functional properties of anti-WNV antibodies using
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Oliphant et al., 2007, 2006; Pierson et al., 2006, 2007; Sanchez et al.,
2007, 2005). Using our approach, standard DNA expression vectors
that encode WNV structural proteins are used to package a WNV
replicon. While the titers achieved using this strategy are modest
(∼107 infectious units (IU)/ml) relative to approaches employing
alphavirus vectors to deliver ﬂavivirus structural proteins, a strength
of this approach is the ability to rapidly mutagenize the structural
protein expression constructs and test the functional properties of
large numbers of variants simply by exchanging the plasmids used
during complementation. Furthermore, the use of a plasmid-based
complementation approach has allowed the production of RVPs that
incorporate different proportions of two different E proteins, a feature
we have exploited to study the stoichiometric requirements for
antibody-mediated neutralization (Pierson et al., 2007) (Mehlhop and
Nelson, submitted).
In this study, we sought to develop and improve methods for the
production of DENV RVPs with a titer and particle-to-infectious-
particle ratio suitable for the study of DENV humoral immune
responses. In agreement with our prior studies, we found that the
direct application of the plasmid complementation approaches used
to produce WNV RVPs were inefﬁcient (Davis et al., 2006a, 2006b;
Whitby et al., 2005) despite efforts to optimize strategies for
introducing the replicon and structural genes into cells. Instead, and
in contrast to WNV, we found that production of DENV RVPs was
strongly temperature-dependent. Production of infectious RVPs at
37 °C was limited by both a more rapid decay of infectious RVPs at this
temperature (relative to lower temperatures and to WNV RVPs) and a
signiﬁcant reduction in the rate of infectious RVP release over time.
Lower temperatures allow for the production of DENV RVPs at a titer
equivalent to those observed with WNV, and ultimately the applica-
tion of these pseudoinfectious particles for the study of DENV
assembly, entry, and the interaction of virions with antibody.
Results and discussion
To develop complementation approaches to produceDENVRVPs,we
constructed a “DNA-launched” DENV replicon using strategies pre-
viously employed for the construction ofWest Nile replicons of a similar
genetic organization (Khromykh et al.,1998b; She et al., 2002; Pierson etFig. 1. Production of DENV RVPs by complementation. (A) DENV RVPs were produced by trans
structural proteins of DENV1 (Western Paciﬁc strain) or DENV2 (16681 strain). Supernatants
measured as a function of the percentage of GFP expressing cells at 72 h post-infection by ﬂo
REx-293-DGZ) that stably propagates a DENV2 sub-genomic replicon. Supernatants were har
using an inducible cell line that stably propagates a DENV2 replicon and expresses DENV stru
DGZ, and T-REx-293-DGZ-WP cells were induced in fresh low glucose media in the presen
transfection and analyzed as in panel A.al., 2006; Scholle et al., 2004). The resulting plasmid encodes a self-
replicating sub-genomic RNA of the DENV serotype 2 (DENV2) strain
16681 that expresses a fusion protein comprised of GFP and zeocin
resistance genes under the control of the CMV immediate-early
promoter. Complementation studies were performed by transfection
of HEK-293T cells with plasmids encoding the replicon and DENV C-
prM-E polyprotein. The titer of infectious RVPs was determined using a
highly permissive Raji cell line that expresses the DENV attachment
protein DCSIGNR (CD209L) (Davis et al., 2006b; Navarro-Sanchez et al.,
2003; Tassaneetrithep et al., 2003). Supernatants harvested from
transfected cells yielded undetectable titers at days one and two post-
transfection, and increased to detectable levels on days three (103 IU/
ml) and four (5×103 IU/ml)(Fig. 1A). By comparison, similar transfection
schemes using WNV vectors routinely result in greater than 107 IU/ml.
To improve the yield of infectious DENV RVPs, two additional
complementation strategies were evaluated. Flaviviruses replicate in
the cytoplasm of infected cells (Lindenbach, 2007). However, the
DENV replicon employed in these experiments are transcribed in the
nucleus and must be exported intact to the cytoplasm, a process that
could be limited by the utilization of splicing signals, or elements that
inhibit RNA export, present in the native DENV2 genomic RNA se-
quence. Therefore, we produced a cell line (T-REx-293-DGZ) that
stably propagates the DENV replicon RNA, and transfected it with a
plasmid encoding the DENV structural proteins. DENV RVP titers
achieved using this approach were similar to those obtained when
transfecting the replicon plasmid directly (Fig. 1B). To address the
possibility that the low titers of DENV RVPs reﬂected limitations in
transfection efﬁciency, we also constructed cell lines that propagate
the DENV replicon and can be induced to express DENV C-prM-E.
Using cell lines expressing either the structural proteins of DENV1 (T-
REx-293-DGZ-WP) or DENV2 (T-REx-293-DGZ-16681) strains, we
were able to produce RVPs in a tetracycline-inducible fashion, albeit
with modest infectious titers (∼103 IU/ml) (Fig. 1C). Titration studies
varying the concentration of tetracycline added to the cell line re-
vealed that the titer of infectious RVPs was relatively constant over a
broad range of induction conditions (Fig. S1). Since each comple-
mentation approach yielded similar low titers of DENV RVPs, we
investigated whether the limitations in DENV RVP production, relative
to our analogous approaches for WNV, may reﬂect other aspects of
DENV virion production, assembly and release.fection of HEK-293Tcells with plasmids encoding a DENV sub-genomic replicon and the
were harvested at the indicated times and titered on Raji-DCSIGNR cells. Infection was
w-cytometry. (B) DENV RVPs were produced by transfection of a T-REx-293 cell line (T-
vested 72 h post-transfection and analyzed as in panel A. (C) DENV RVPs were produced
ctural proteins in a tetracycline dependent fashion. Parental T-REx-293 cells, T-REx-293-
ce (+) or absence (−) of 1 μg/ml tetracycline. Supernatants were harvested 72 h post-
Fig. 2. Temperature-dependent production of RVPs. (A) DENV1 RVPs were produced by induction of T-REx-293-DGZ-WP cells with tetracycline, followed by culture at the indicated
temperatures. Culture supernatants were collected at the indicated times post-induction and titered using Raji-DCSIGNR cells. Infectionwasmeasured as a function of the percentage
of GFP expressing cells at 72 h post-infection by ﬂow-cytometry. (B) WNV RVPs were produced by transfection of HEK-293T cells with plasmids encoding a sub-genomic WNV
replicon and WNV C-prM-E. Supernatants were collected at the indicated times post-transfection and titered as described above. (C) DENV1 RVPs that encapsidate a WNV genome
were produced by transfection of HEK-293T cells with plasmids encoding a sub-genomic WNV replicon and DENV1 C-prM-E (Western Paciﬁc strain). DENV RVPs were harvested at
the indicated times and titered as described above. (D–F) To obtain a more quantitatively rigorous understanding of the temperature-dependent differences in DENV and WNV RVP
production, RVPs were produced in replicate wells of a 6-well plate as described for A–C. RVP-containing supernatants were collected at 24 h and 48 h after induction and titered
using Raji-DCSIGNR cells in triplicate. Infection is expressed relative to the titer achieved at 48 h post-infection at 37 °C. Error bars reﬂect the standard error of two independent
production experiments.
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Because protein stability and folding efﬁciency may be greater
at lower temperatures, we investigated whether more efﬁcient
DENV RVPs production could be achieved at reduced temperatures.
T-REx-293-DGZ-WP cells were inducedwith tetracycline, incubated at
the indicated temperatures and sampled for the release of infectious
RVPs over the course of several days (Fig. 2A). Cells incubated at lower
temperatures produced infectious RVPs more slowly than those
incubated at 37 °C, consistent with the slower kinetics of structural
gene expression in cells at lower temperatures (data not shown). In
contrast, production of DENV RVPs at 37 °C was relatively transient
and achieved modest titers relative to the peak RVP titers achieved
using lower temperatures (Fig. 2A). The titer of DENV RVPs inFig. 3. Temperature-dependent changes in the rate of DENV RVP production. The rate of infe
investigated. DENV RVPs were produced by induction of T-REx-293-DGZ-WP cells (A) and W
theMaterials and methods. Culture supernatants were removed from duplicate wells at 22 h
equilibrated at the indicated temperature. Supernatant was collected 4 h later and titered in d
GFP expressing cells at 72 h (A) or 48 h (B) post-infection by ﬂow-cytometry. The data pressupernatants of cells at 37 °C decreased signiﬁcantly (46.6±0.1 fold,
n=6, pb0.0001) between 24 and 48 h (Fig. 2D), whereas titers at 28 °C
and 30 °C increased during the same time frame ((16.4±0.4 fold,
p=0.0004) and (3.4±0.3 fold, p=0.0012) for 28 °C and 30 °C,
respectively). By comparison, while the kinetics of WNV RVP
production were also affected by temperature in a similar fashion,
WNV RVP infectious titers at both 24 and 48 h were similar (Figs. 2B
and 2E). Furthermore, that the production of DENV RVPs by HEK-293T
cells transfected with DENV structural genes and a WNV replicon was
also transient at 37 °C (Figs. 2C and 2F) suggests the rapid decrease in
DENV RVP titers released from T-REx-293-DGZ-WP cells does not
reﬂect unique properties of the DENV replicon packaged by these
particles nor the inducible cell line used to produce them. We noted
that the kinetics of RVPs released from transfected cells are slightlyctious DENV and WNV RVP production at 24 and 48 h post-induction/transfection was
NV RVPs were produced by transfection of HEK-293T cells (B) as described in Fig. 2 and
(d1) or 46 h (d2) post-induction and immediately replaced with conditioned media pre-
uplicate using Raji-DCSIGNR cells. Infectionwasmeasured as a function of the percent of
ented is representative of three independent experiments.
Fig. 4. Stability of WNV and DENV RVPs. (A) DENV RVPs were produced using T-REx-293-DGZ-WP cells and aliquoted (500 μl) into wells of a 48-well plate. Plates were incubated at
the indicated temperatures. At the indicated times, RVPs were removed from duplicate wells and frozen at −80 °C. The titer of RVPs from each time point was determined
simultaneously by infecting Raji-DCSIGNR cells with serial two-fold dilutions of RVPs in complete RPMI-1640medium. Infectionwasmeasured as a function of GFP expression at 72 h
post-infection by ﬂow-cytometry. Non-linear regression analysis was performed to generate one-phase exponential decay curves using GraphPad Prism version 4.0b. Dotted lines
indicate the 95% conﬁdence interval for the regression analysis. (B) The average half-life of WNV and DENV RVPs at 28 °C or 37 °C is displayed. Error bars indicate the standard error of
multiple independent measurements of the stability of DENV and WNV at each temperature (n=6 and n=7 for DENV and WNV at 28 °C; n=7 and n=4 for DENV and WNV at 37 °C).
Statistical comparisons were made using GraphPad Prism version 4.0b (unpaired t test).
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required for transcription of the WNV DNA “launched” replicon RNA
and the initiation of replicon RNA replication. This was not due to an
intrinsic difference in the replication rate between WNV and DENV
replicons, as the former replicates faster and to higher levels than the
DENV replicon (Fig. S2).
To investigate the mechanisms that limit the duration and overall
titer of DENV RVP production at 37 °C, we next measured the rate of
RVP release from producer cells, and their decay in culture super-Fig. 5. Infection of a panel of cell lines with DENV RVPs. (A) WNV and DENV RVPs were pr
encoding either WNV (blue) or DENV2 16881 (red) structural genes. Serial four-fold dilutions
and methods section. Infectionwas scored as a function of Renilla luciferase activity 48 h post
the standard error. (B) The infectivity of each population of RVPs was normalized as a functio
using real-time qRT-PCR as described (Geiss et al., 2005; Houng et al., 2001).natants. The rate of virion release was estimated by measuring the
titer of RVPs produced from cells during a four-hour window at 24 or
48 h post-induction or transfection (DENV andWNV, respectively). As
suggested by our longitudinal and cross-sectional studies above (Figs.
2A and 2B), the rate of infectious DENV RVP production decreased
signiﬁcantly between days one and two for cells cultured at 37 °C (99.5±
0.1 fold, p=0.0032)(Fig. 3A), corresponding to the dramatic decrease
in infectious DENV RVP titer present in culture supernatants by day
two observed in longitudinal and cross-sectional sampling (Fig. 2A).oduced in HEK-293T cells transfected with a WNV sub-genomic replicon and plasmids
of RVPs were used to infect each cell line in quadruplicate as described in the Materials
-infection. The signal obtained with undiluted RVPs is shown, with error bars indicating
n of the relative genomic RNA content of each preparation. Genomic RNAwas measured
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modestly reduced during the same interval. Infectious DENV RVP
release from T-REx-293-DGZ-WP cells incubated at 28 °C and 30 °C
increased signiﬁcantly between day one and two (5.74±0.04 fold,
p=0.0022, and 1.94±0.04 fold, p=0.0057, respectively). Analysis of the
decay of the infectivity of DENV RVPs at each production temperature
indicates that they are signiﬁcantly less stable at 37 °C (T1/2=8.3 h,
n=7) as compared to 28 °C (T1/2=34.2 h, n=6)(pb0.0001)(Fig. 4).
WNV RVPs are signiﬁcantly more stable than DENV RVPs at both
28 °C (T1/2=65.7 h, n=4) (p=0.0025) and 37 °C (T1/2=15.1 h, n=4)
(p=0.0294).
Together, our data indicates that differences in the efﬁciency of
WNV and DENV RVP production reﬂect both the dynamics of RVP
production and differences in the stability of infectious RVPs at 37 °C.
The titer of DENV RVPs produced at 37 °C is limited due to the
transient release of virions by cells as measured functionally (Fig. 3A)
and by the presence of RVP-associated replicon RNA in the super-
natant (Fig. S3). Why DENV RVP producing cells stop releasing in-
fectious virus particles is presently unclear, but does not appear to
reﬂect overt cytotoxicity conferred by DENV protein expression. LDH-
release from RVP producing cells increased onlymodestly with time at
37 °C, and was not dependent upon DENV structural gene expression.
The level of replicon replication in 293T producer cells also decreased
with time in culture at this temperature (∼2-fold) (Fig. S4). As neither
change in producer cell phenotype occurred with kinetics that parallel
the rapid reduction of DENV RVP production observed above, it
remains unclear whether these factors govern RVP production ef-
ﬁciency, or reﬂect changes that occur during prolonged culture of
293T cells at high density. Instead, the transient production of DENV
RVPs at 37 °C revealed by longitudinal sampling (Fig. 2A) can be
explained by the termination of infectious RVP release shortly after
day one post-induction/transfection, followed by the decay of virions
already released into the media with a half-life of approximately 8 h.
Production at lower temperatures is more efﬁcient because it in-
creases the time during which producer cells release DENV RVPs, as
well as decreases the rate of virion decay in the culture supernatant.
Infection of multiple cell lines with DENV RVPs
The expression of DCSIGN (CD209) and DCSIGNR (CD209L) on cell
lines has been shown to signiﬁcantly increase the efﬁciency of DENV
infection, reﬂecting the role of these lectins in promoting more
efﬁcient and durable attachment of the virus to target cells (Navarro-
Sanchez et al., 2003; Tassaneetrithep et al., 2003). Thus, to maximize
the sensitivity of our RVP production optimization experiments we
utilized a cell line that expresses DCSIGNR.We next explored whetherFig. 6.Measuring antibody-mediated neutralization using DENV RVPs. (A) To demonstrate th
that satisfy the law of mass action (Andrewes, 1933; Klasse and Sattentau, 2001; Pierson et a
for 1 h at room temperaturewith serial dilutions of DENV1 RVPs. RVP-antibody complexeswe
GFP expression using ﬂow-cytometry. Error bars display the standard error of triplicate infec
from T-REx-293-DGZ-WP cells and by plasmid transfection are neutralized equivalently. Dose
as described above. (C) The neutralization titer of antibody present in the pooled DENV1 or
calculated from independent dose response curves composed of nine dilutions of sera perfor
the standard error.DENV RVPs produced using the plasmid complementation approach
described above were capable of infecting cell lines that do not
express known attachment factors, including those commonly
employed in studies of ﬂaviviruses (BHK21 and Vero). DENV and
WNV RVPs were produced by transfection of HEK-293Ts with
plasmids encoding the structural proteins of either virus and a WNV
replicon encoding the Renilla luciferase gene. The rationale for the
selection of a WNV replicon was: i.) our studies described above did
not suggest that the use of a heterologous replicon was associated
with a signiﬁcant reduction in RVP titer (compare Figs. 2B and C), ii.) to
control for post-entry differences in replication between DENV and
WNV, and iii.) the kinetics of reporter gene expression by WNV
replicons is more rapid than that observed with DENV replicons of
similar design (25 h vs 98 h for WNV and DENV replicons, res-
pectively). Serial four-fold dilutions of RVPs were used to infect eleven
cell lines of varying origin. Analysis of the signal obtained at the
highest RVP dilution tested indicates varying degrees of permissive-
ness, as expected from published studies (Fig. 5) (Anderson, 2003;
Clyde et al., 2006; Diamond et al., 2000). Signals greater than 1000-
fold above background were obtained for both DENV and WNV RVPs
on themost permissive lines, whereas infection of the Jurkat T cell line
was not observed with either WNV or DENV RVPs. To get a more
precise estimate of the relative infectivity of DENV and WNV RVPs on
these lines, we next measured the genome content of each prepara-
tion and used the resulting data to normalize the level of infectivity
between the two types of virus particles. To our surprise, we found
that the ratio between infectivity and the relative numbers of replicon
genomes in stocks of DENV RVPs was relatively low as compared to
WNV RVPs, despite the similar infectious titers observed using several
different cell lines (Fig. 5B). Interestingly, as a function of the relative
number of genome copies, DENV RVPs were more infectious than
WNV in certain cell lines (e.g. BHK) that do not express any known
ﬂavivirus attachment factor, suggesting that these particular strains of
DENV (16681) and WNV (NY99) might utilize distinct attachment
factors to infect certain cell lines (Fig. 5B).
Neutralization of DENV RVPs
We have employed WNV RVPs extensively to investigate the
functional properties and mechanisms of action of neutralizing
antibodies (Mehlhop et al., 2007; Nelson et al., 2008; Oliphant et al.,
2007, 2006; Pierson et al., 2006, 2007). The key parameter that
governs the precision and reproducibility of RVP-basedmeasurements
of neutralization is the ability to measure the outcome of antibody–
virion interactions under conditions that satisfy the law of mass action
(“antibody excess”) (Andrewes, 1933; Klasse and Sattentau, 2001;at RVPs allow for the study of the functional properties of antibodies under conditions
l., 2006), nine serial four-fold dilutions of DENV1-immune primate sera were incubated
re then added to Raji-DCSIGNR cells in triplicate. Infectionwasmeasured as a function of
tions. Non-linear regression analysis was used to calculate the EC50. (B) RVPs produced
response curves were generated using DENV1 or DENV2 (data not shown) immune sera
DENV2-immune sera is shown. The error bar represents the average reciprocal dilution
med in duplicate (DENV1, n=12 and DENV2, n=4, respectively). The error bar represents
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with a particle-to-infectious-particle ratio such that the concentration
of antigen in RVP preparations is negligible with respect to the afﬁnity
of the antibodies investigated. This can be validated simply by
studying the neutralization potency of antibodies using multiple
concentrations of RVPs (Pierson et al., 2006). To validate the utility of
our DENV RVP production approaches, we performed neutralization
studies with three different concentrations of DENV1 RVPs produced
in the T-REx-293-DGZ-WP cell line, and DENV1 immune sera obtained
from experimentally-infected rhesus macaques (Whitehead et al.,
2003). A similar study was also performed using DENV2 RVPs and
DENV2 immune sera from experimentally-infected macaques (data
not shown) (Blaney et al., 2004). Signiﬁcant differences in neutraliza-
tion titer were not observed with increasing dilution (Fig. 6A), nor
were differences noted when DENV1 (Fig. 6B) or DENV2 (data not
shown) RVPs produced by transfection or induction of our stable cell
lines were studied in parallel. Overall, the variability of repeated
assays of DENV1 (n=12) and DENV2 (n=4) immune sera using RVPs of
the same serotype was approximately 15 and 26 percent of the
average value, respectively (Fig. 6C). Together, these results highlight
the utility of DENV for studying the functional properties of DENV
neutralizing antibodies.
Concluding remarks
Pseudoinfectious reporter viruses that allow virus entry to be
measured as a function of reporter gene expression have been
employed extensively for many viruses, including ﬂaviviruses. WNV
RVPs produced by genetic complementation have provided an
extremely quantitative and high-throughput approach for the study
of antibody-mediated neutralization. While the direct application of
these methods for the production of DENV RVPs was possible, by
comparison toWNV, they were inefﬁcient and of limited utility (Davis
et al., 2006a, 2006b; Whitby et al., 2005). The identiﬁcation of factors
that limit the production of infectious DENV RVPs allowed the pro-
duction of DENV RVPs with a sufﬁcient titer to allow study of the
functional properties of DENV antibodies (Mehlhop et al., 2007). In
addition, the development of stable cell lines that can be induced to
produce pseudoinfectious DENV RVPs represents a novel, low-cost
approach that may be appropriately scaled to allow the study of
the immune response of large numbers of infected or vaccinated
individuals.
Materials and methods
Maintenance and production of cell lines
All cell lines were grown at 37 °C in the presence of 7% CO2. HEK-
293T, HeLa, BHK21, HT1080, and Huh-7 cell lines were passaged in
complete Dulbecco's modiﬁed Eagle medium (DMEM)(complete
DMEM: DMEM containing Glutamax and 25 mM Hepes, supplemen-
ted with 10% fetal bovine serum (FBS)(HyClone, Logan, UT) and 100 U/
ml penicillin–streptomycin (PS)). K562, Jurkat, and Raji cell lines were
maintained in complete RPMI-1640 medium (complete RPMI)
supplemented with 10% FBS and 100 U/ml penicillin–streptomycin.
K562 and Raji lines that stably express DC-SIGN or DCSIGNR have been
described elsewhere (Davis et al., 2006b; Pierson et al., 2007). Vero
cells were cultured in complete Minimum Essential Medium (com-
plete MEM) containing 10% FBS and 100 U/ml PS.
HEK-293T cell lines that stably propagate DENV replicons and can
be induced to produce DENV RVPs were produced using Invitrogen's
T-REx-293 cell lines that constitutively express the Tet repressor.
Parental T-REx-293 cell lines were propagated in complete DMEM
supplemented with 5 μg/ml blasticidin S. A T-REx-293 cell line that
stably propagates a DENV repliconwas produced by infecting parental
T-REx-293 cells with RVPs that encapsidate the DENV replicon,followed by selection in the presence of 5 μg/ml blasticidin S and
300 μg/ml zeocin (creating the T-REx-293-DGZ cell line). Inducible cell
lines that release DENV RVPs were produced by transfection of the T-
REx-293-DGZ cell line with plasmids that express the C-prM-E
proteins of DENV strains Western Paciﬁc (DENV1) and 16681
(DENV2). The resulting cell lines were selected and passaged in
complete DMEM supplemented with 5 μg/ml blasticidin S, 300 μg/ml
zeocin, and 500 μg/ml G418.
Plasmids
The WNV sub-genomic replicon and C-prM-E expression plasmid
used throughout the study were described previously (Pierson et al.,
2006). The DENV2 repliconwas constructed as described below. DENV
C-prM-E expression constructs (Western Paciﬁc and 16681 strains)
were constructed by topoisomerase mediated cloning into the pENTR/
D Gateway cloning entry vector. Inserts were sequenced and then
transferred into pcDNA 6.2 and pT-REx-DEST30 destination vectors.
The latter vector was used to construct the tetracycline-inducible cell
lines described above.
Construction of a DNA-launched DENV2 replicon
A sub-genomic DENV2 repliconwas constructed bymodiﬁcation of
a molecular clone of the DENV2 strain 16681 using an approach
described initially by Varnavski et al. (2000). Starting material for the
work was the pD2/IC-30Pmolecular clone of the 16681 strain of DENV
(Kinney et al., 1997). First, the majority of sequence encoding the
structural genes of 16681 was deleted, and the T7 promoter of the
pD2/IC-30P construct was replaced with the CMV immediate-early
promoter/enhancer. To do this in the smallest number of steps, we
performed overlapping PCR to fuse a fragment of a previously de-
scribed sub-genomic WNV replicon that encodes the CMV promoter,
WNV 5′ untranslated region, a small portion of the WNV capsid, and
FMDV 2a autoprotease, and a MluI site with the DEN ORF (Pierson
et al., 2006). The resulting PCR fragment was cleaved at BstX1 and
MluI sites engineered into the primers and inserted into the pD2/IC-
30P vector using unique SacI and KpnI sites. Importantly, the SacI site
present in pD2/IC-30P was destroyed during this step, allowing the
replacement of the WNV sequence in this cloning intermediate with
sequence encoding the DEN 5′ UTR and 24 residues of DENV capsid.
This was accomplished using a single PCR fragment and novel SacI and
MluI sites engineered into the primers. The ribozyme of hepatitis delta
virus (HDV) was then introduced into the 3′ end of the replicon using
overlap extension PCR and introduced into the replicon via unique
AvrII and ClaI sites present in the vector backbone. Subsequently, a
GFP/Zeocin resistance reporter genewas inserted into the uniqueMluI
site located just downstream of the FMDV2a autoprotease.
Production of reporter virus particles
RVPs were generated using two different approaches: i.) by
transfection with plasmids encoding a sub-genomic replicon and
structural genes (C-prM-E) as described (Pierson et al., 2006), or ii.) by
induction of C-prM-E expression in 293T-Rex cell lines that stably
propagate a DENV2 replicon. Production of RVPs by transfection was
accomplished by introducing plasmids encoding a replicon and
structural proteins (in a 1:2 ratio, by mass) into pre-plated HEK-293T
cells using Lipofectamine 2000. RVPswere also produced by transfection
of T-REx-293-DGZ cells with plasmids encoding DENV structural
proteins. Four hours after transfection, culture media was removed and
replaced with a low glucose formulation of DMEM containing 10% FBS
and 100 U/ml PS and incubated at the indicated temperatures. RVP
production using T-REx-293-DGZ-WP or T-REx-293-DGZ-16681 induci-
ble cells lineswas achieved following the addition of 1 μg/ml tetracycline.
Using optimal production conditions for DENV RVPs, transfected cells
73C. Ansarah-Sobrinho et al. / Virology 381 (2008) 67–74were incubated at 30 °C for approximately 72 h. RVP-containing
supernatants were harvested, ﬁltered using a 0.22 μm syringe ﬁlter
and stored at −80 °C in complete low glucose DMEM.
RVP infections
The infectious titer of RVPs was typically determined by using Raji-
DCSIGNR cells. Serial two-fold dilutions of RVPs were prepared using
complete RPMI, and then added to Raji-DCSIGNR cells plated in 96-
well plates at 5×104 cells per well on the day of the assay. Infections
were performed in a total volume of 200 μl. The percentage of cells
infected at each dilution was scored as a function of GFP expression
using ﬂow-cytometry two days (when RVPs package a WNV replicon)
or three days (when RVPs package a DENV replicon) post-infection.
The rationale for performing serial dilutions of virus in each
experiment reﬂects the lack of a linear relationship between virus
dilution and the percentage of infected cells at all dilutions. In all
cases, comparisons between RVP preparations were made at dilutions
on the linear parts of the infection–dilution curve.
To compare the relative capacity of different cell lines to support E
protein-mediated WNV or DENV entry, adherent cells were plated the
day before the assay in 48-well plates ((BHK21, H1080, Huh-7 (20 k
cells/well); Vero (30 k cells/well); HEK293T (40 k cells/well)). On the
next day, media was removed and cells were infected with 100 μl of
serial four-fold dilutions of RVPs. Cells were cultured at 37 °C
overnight, and then media was replaced with 200 μl of a low glucose
formulation of DMEM. In contrast, suspension cell lines (Raji, K562,
and Jurkat) were plated in 96-well plates on the day of the assay (50 k
cells/well) and infected with serial dilutions of RVPs (200 μl total
volume). The relative infectivity was measured as a function of Renilla
luciferase reporter gene expression at two days post-infection
according to the manufacturers instructions.
Western blotting
Envelope protein expression in RVP-producing cells was detected
byWestern blot using the ﬂavivirus pan-speciﬁc monoclonal antibody
4G2. Cells were lysed in 200 μl cell lysis buffer (1×PBS; 50 mM Tris.
HCl; 150 mM NaCl; 2 mM EDTA; 1% Triton-X; protease inhibitor
cocktail), spun brieﬂy to remove cellular debris, and analyzed by BCA
following the manufacturer's protocol (BCA Protein Assay Kit—Pierce).
Roughly 50 μg of total protein was analyzed by SDS-PAGE under non-
reducing conditions and immunoblotted with 4G2 at 1 μg/ml.
Quantitative real-time PCR
The genomic RNA content of RVP populations was measured
using a modiﬁcation of a previously described protocol (Hanna et al.,
2005). Brieﬂy, RVP-containing supernatants were treated with 100 U
recombinant DNAse I, followed by RNA isolation using the QiaAmp
Viral RNA kit per the manufacturers instructions (Qiagen, Hilden,
GE). Ampliﬁcation of viral genomic RNAwas accomplished using the
Superscript III one-step RT-PCR system (Invitrogen, Carlsbad, CA)
and primers speciﬁc for either the 3′ untranslated region of WNV
lineage II replicon (Geiss et al., 2005) or dengue 2 replicon (Houng
et al., 2001).
Neutralization of DV reporter virus particles
Neutralization of DENV RVPs was performed as described
previously for WNV RVPs (Nelson et al., 2008; Pierson et al., 2006,
2007). Experiments using RVPs encapsidating a WNV replicon were
analyzed on day two, whereas studies employing a DENV replicon
were analyzed on day three. Antibody potency was calculated from
dose–response data by non-linear regression analysis using GraphPad
Prism v4.0b as described (Pierson et al., 2007).Acknowledgments
This work was supported by the Intramural Research Program of
the NIH, National Institutes of Allergy and Infectious Diseases (NIAID)
and by the Pediatric Dengue Vaccine Initiative (PDVI). We are grateful
to Qing Xu for technical support and Dr. Bridget Puffer for providing
the DENV C-prM-E expression vectors used throughout this study, for
excellent technical assistance, and productive discussions. We thank
Drs. Christopher Buck, Subhajit Poddar, and Michael Diamond for
useful discussions and their comments on the manuscript.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.virol.2008.08.021.
References
Alvarez, M., Rodriguez-Roche, R., Bernardo, L., Vazquez, S., Morier, L., Gonzalez, D.,
Castro, O., Kouri, G., Halstead, S.B., Guzman, M.G., 2006. Dengue hemorrhagic fever
caused by sequential dengue 1–3 virus infections over a long time interval: Havana
epidemic, 2001–2002. Am. J. Trop. Med. Hyg. 75 (6), 1113–1117.
Anderson, R., 2003. Manipulation of cell surface macromolecules by ﬂaviviruses. Adv.
Virus Res. 59, 229–274.
Andrewes, C.H.a.E., W.J., 1933. Observations on anti-phage sera. I. ‘The percentage law’.
Br. J. Exp. Pathol. 14, 367–376.
Blaney Jr., J.E., Hanson, C.T., Hanley, K.A., Murphy, B.R., Whitehead, S.S., 2004. Vaccine
candidates derived from a novel infectious cDNA clone of an American genotype
dengue virus type 2. BMC. Infect Dis. 4, 39.
Clyde, K., Kyle, J.L., Harris, E., 2006. Recent advances in deciphering viral and host
determinants of dengue virus replication and pathogenesis. J. Virol. 80 (23),
11418–11431.
Davis, C.W., Mattei, L.M., Nguyen, H.Y., Ansarah-Sobrinho, C., Doms, R.W., Pierson, T.C.,
2006a. The Location of asparagine-linked glycans on West Nile virions controls
their interactions with CD209 (dendritic cell-speciﬁc ICAM-3 grabbing noninte-
grin). J. Biol. Chem. 281 (48), 37183–37194.
Davis, C.W., Nguyen, H.Y., Hanna, S.L., Sanchez, M.D., Doms, R.W., Pierson, T.C., 2006b.
West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular
attachment and infection. J. Virol. 80 (3), 1290–1301.
Diamond, M.S., Edgil, D., Roberts, T.G., Lu, B., Harris, E., 2000. Infection of human cells by
dengue virus is modulated by different cell types and viral strains. J. Virol. 74 (17),
7814–7823.
Endy, T.P., Nisalak, A., Chunsuttitwat, S., Vaughn, D.W., Green, S., Ennis, F.A., Rothman, A.L.,
Libraty, D.H., 2004. Relationship of preexisting dengue virus (DV) neutralizing
antibody levels to viremia and severity of disease in a prospective cohort study of
DV infection in Thailand. J. Infect Dis. 189 (6), 990–1000.
Fayzulin, R., Scholle, F., Petrakova, O., Frolov, I., Mason, P.W., 2006. Evaluation of
replicative capacity and genetic stability of West Nile virus replicons using highly
efﬁcient packaging cell lines. Virology 351 (1), 196–209.
Gehrke, R., Ecker, M., Aberle, S.W., Allison, S.L., Heinz, F.X., Mandl, C.W., 2003.
Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a
packaging cell line. J. Virol. 77 (16), 8924–8933.
Geiss, B.J., Pierson, T.C., Diamond, M.S., 2005. Actively replicating West Nile virus is
resistant to cytoplasmic delivery of siRNA. Virol. J. 2, 53.
Goto, A., Yoshii, K., Obara, M., Ueki, T., Mizutani, T., Kariwa, H., Takashima, I., 2005. Role
of the N-linked glycans of the prM and E envelope proteins in tick-borne
encephalitis virus particle secretion. Vaccine 23 (23), 3043–3052.
Gubler, D.J., Meltzer, M., 1999. Impact of dengue/dengue hemorrhagic fever on the
developing world. Adv. Virus Res. 53, 35–70.
Gubler, D., K.G., Markoff, L., 2007. Flaviviruses, In: H.P., Knipe, D.M., Grifﬁn, D.E., Lamb,
R.A., Martin, M.A. (Eds.), 5th. Fields Virology, 1. Lippincott Wlliams & Wilkins,
Philadelphia, pp. 1153–1252. 2 vols.
Halstead, S.B., 2003. Neutralization and antibody-dependent enhancement of dengue
viruses. Adv. Virus Res. 60, 421–467.
Hanna, S.L., Pierson, T.C., Sanchez, M.D., Ahmed, A.A., Murtadha, M.M., Doms, R.W.,
2005. N-linked glycosylation of West Nile virus envelope proteins inﬂuences
particle assembly and infectivity. J. Virol. 79 (21), 13262–13274.
Harvey, T.J., Liu, W.J., Wang, X.J., Linedale, R., Jacobs, M., Davidson, A., Le, T.T.,
Anraku, I., Suhrbier, A., Shi, P.Y., Khromykh, A.A., 2004. Tetracycline-inducible
packaging cell line for production of ﬂavivirus replicon particles. J. Virol. 78 (1),
531–538.
Hayasaka, D., Yoshii, K., Ueki, T., Iwasaki, T., Takashima, I., 2004. Sub-genomic replicons
of Tick-borne encephalitis virus. Arch. Virol. 149 (6), 1245–1256.
Houng, H.S., Chung-Ming Chen, R., Vaughn, D.W., Kanesa-thasan, N., 2001. Development
of a ﬂuorogenic RT-PCR system for quantitative identiﬁcation of dengue virus
serotypes 1–4 using conserved and serotype-speciﬁc 3′ noncoding sequences. J.
Virol. Methods 95 (1–2), 19–32.
Jones, C.T., Patkar, C.G., Kuhn, R.J., 2005. Construction and applications of yellow fever
virus replicons. Virology 331 (2), 247–259.
Khromykh, A.A., Westaway, E.G., 1997. Subgenomic replicons of the ﬂavivirus Kunjin:
construction and applications. J. Virol. 71 (2), 1497–1505.
74 C. Ansarah-Sobrinho et al. / Virology 381 (2008) 67–74Khromykh, A.A., Kenney, M.T., Westaway, E.G., 1998a. trans-Complementation of
ﬂavivirus RNA polymerase gene NS5 by using Kunjin virus replicon-expressing BHK
cells. J. Virol. 72 (9), 7270–7279.
Khromykh, A.A., Varnavski, A.N., Westaway, E.G., 1998b. Encapsidation of the ﬂavivirus
kunjin replicon RNA by using a complementation system providing Kunjin virus
structural proteins in trans. J. Virol. 72 (7), 5967–5977.
Kinney, R.M., Butrapet, S., Chang, G.J., Tsuchiya, K.R., Roehrig, J.T., Bhamarapravati, N.,
Gubler, D.J., 1997. Construction of infectious cDNA clones for dengue 2 virus: strain
16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230 (2),
300–308.
Klasse, P.J., Sattentau, Q.J., 2001. Mechanisms of virus neutralization by antibody. Curr.
Top Microbiol. Immunol. 260, 87–108.
Lai, C.Y., Hu, H.P., King, C.C., Wang, W.K., 2008. Incorporation of dengue virus replicon
into virus-like particles by a cell line stably expressing precursor membrane and
envelope proteins of dengue virus type 2. J. Biomed. Sci. 15 (1), 15–27.
Lindenbach, B.D., Thiel, H.J., Rice, C.M., 2007. Flaviviridae: the viruses and their replication,
In: H.P.M., D.M., Knipe, Grifﬁn, D.E., Lamb, R.A., Martin, M.A. (Eds.), 5th. Fields Virology,
1. Lippincott Williams & Wilkins, Philadelphia, pp. 1101–1152. 2 vols.
Mackenzie, J.S., Gubler, D.J., Petersen, L.R., 2004. Emerging ﬂaviviruses: the spread and
resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10 (12
Suppl), S98–109.
Mehlhop, E., Ansarah-Sobrinho, C., Johnson, S., Engle, M., Fremont, D.H., Pierson, T.C.,
Diamond, M.S., 2007. Complement protein C1q inhibits antibody-dependent
enhancement of ﬂavivirus infection in an IgG subclass-speciﬁc manner. Cell Host
Microbe 2 (6), 417–426.
Molenkamp, R., Kooi, E.A., Lucassen, M.A., Greve, S., Thijssen, J.C., Spaan, W.J.,
Bredenbeek, P.J., 2003. Yellow fever virus replicons as an expression system for
hepatitis C virus structural proteins. J. Virol. 77 (2), 1644–1648.
Monath, T.P., 2007. Dengue and yellow fever-challenges for the development and use of
vaccines. N. Engl. J. Med. 357 (22), 2222–2225.
Mongkolsapaya, J., Dejnirattisai, W., Xu, X.N., Vasanawathana, S., Tangthawornchaikul,
N., Chairunsri, A., Sawasdivorn, S., Duangchinda, T., Dong, T., Rowland-Jones, S.,
Yenchitsomanus, P.T., McMichael, A., Malasit, P., Screaton, G., 2003. Original
antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever.
Nat. Med. 9 (7), 921–927.
Navarro-Sanchez, E., Altmeyer, R., Amara, A., Schwartz, O., Fieschi, F., Virelizier, J.L.,
Arenzana-Seisdedos, F., Despres, P., 2003. Dendritic-cell-speciﬁc ICAM3-grabbing
non-integrin is essential for the productive infection of human dendritic cells by
mosquito-cell-derived dengue viruses. EMBO. Rep. 4 (7), 723–728.
Nelson, S., Jost, C.A., Xu, Q., Ess, J., Martin, J.E., Oliphant, T., Whitehead, S.S., Durbin, A.P.,
Graham, B.S., Diamond, M.S., Pierson, T.C., 2008. Maturation of West Nile virus
modulates sensitivity to antibody-mediated neutralization. PLOS Pathogens 4,
e1000060.
Oliphant, T., Nybakken, G.E., Engle, M., Xu, Q., Nelson, C.A., Sukupolvi-Petty, S., Marri, A.,
Lachmi, B.E., Olshevsky, U., Fremont, D.H., Pierson, T.C., Diamond, M.S., 2006.
Antibody recognition and neutralization determinants on domains I and II of West
Nile Virus envelope protein. J. Virol. 80 (24), 12149–12159.
Oliphant, T., Nybakken, G.E., Austin, S.K., Xu, Q., Bramson, J., Loeb, M., Throsby, M.,
Fremont, D.H., Pierson, T.C., Diamond, M.S., 2007. Induction of epitope-speciﬁc
neutralizing antibodies against West Nile virus. J. Virol. 81 (21), 11828–11839.
Pang, X., Zhang, M., Dayton, A.I., 2001. Development of Dengue virus type 2 replicons
capable of prolonged expression in host cells. B.M.C. Microbiol. 1, 18.
Pierson, T.C., Diamond, M.S., Ahmed, A.A., Valentine, L.E., Davis, C.W., Samuel, M.A.,
Hanna, S.L., Puffer, B.A., Doms, R.W., 2005. An infectious West Nile virus that
expresses a GFP reporter gene. Virology 334 (1), 28–40.Pierson, T.C., Sanchez, M.D., Puffer, B.A., Ahmed, A.A., Geiss, B.J., Valentine, L.E.,
Altamura, L.A., Diamond, M.S., Doms, R.W., 2006. A rapid and quantitative assay for
measuring antibody-mediated neutralization of West Nile virus infection. Virology
346 (1), 53–65.
Pierson, T.C., Xu, Q., Nelson, S., Oliphant, T., Nybakken, G.E., Fremont, D.H., Diamond,
M.S., 2007. The stoichiometry of antibody-mediated neutralization and enhance-
ment of West Nile virus infection. Cell Host Microbe 1 (2), 135–145.
Rothman, A.L., 2004. Dengue: deﬁning protective versus pathologic immunity. J. Clin.
Invest. 113 (7), 946–951.
Sanchez, M.D., Pierson, T.C., McAllister, D., Hanna, S.L., Puffer, B.A., Valentine, L.E.,
Murtadha, M.M., Hoxie, J.A., Doms, R.W., 2005. Characterization of neutralizing
antibodies to West Nile virus. Virology 336 (1), 70–82.
Sanchez, M.D., Pierson, T.C., Degrace, M.M., Mattei, L.M., Hanna, S.L., Del Piero, F., Doms,
R.W., 2007. The neutralizing antibody response against West Nile virus in naturally
infected horses. Virology 359 (2), 336–348.
Scholle, F., Girard, Y.A., Zhao, Q., Higgs, S., Mason, P.W., 2004. trans-Packaged West Nile
virus-like particles: infectious properties in vitro and in infected mosquito vectors.
J. Virol. 78 (21), 11605–11614.
Shi, P.Y., Tilgner, M., Lo, M.K., 2002. Construction and characterization of subgenomic
replicons of New York strain of West Nile virus. Virology 296 (2), 219–233.
Stephens, H.A., Klaythong, R., Sirikong, M., Vaughn, D.W., Green, S., Kalayanarooj, S.,
Endy, T.P., Libraty, D.H., Nisalak, A., Innis, B.L., Rothman, A.L., Ennis, F.A.,
Chandanayingyong, D., 2002. HLA-A and -B allele associations with secondary
dengue virus infections correlate with disease severity and the infecting viral
serotype in ethnic Thais. Tissue Antigens 60 (4), 309–318.
Tassaneetrithep, B., Burgess, T.H., Granelli-Piperno, A., Trumpfheller, C., Finke, J., Sun,W.,
Eller, M.A., Pattanapanyasat, K., Sarasombath, S., Birx, D.L., Steinman, R.M.,
Schlesinger, S., Marovich, M.A., 2003. DC-SIGN (CD209) mediates dengue virus
infection of human dendritic cells. J. Exp. Med. 197 (7), 823–829.
Varnavski, A.N., Young, P.R., Khromykh, A.A., 2000. Stable high-level expression of
heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus
replicon vectors. J. Virol. 74 (9), 4394–4403.
Vaughn, D.W., Green, S., Kalayanarooj, S., Innis, B.L., Nimmannitya, S., Suntayakorn, S.,
Endy, T.P., Raengsakulrach, B., Rothman, A.L., Ennis, F.A., Nisalak, A., 2000. Dengue
viremia titer, antibody response pattern, and virus serotype correlate with disease
severity. J. Infect Dis. 181 (1), 2–9.
Whitby, K., Pierson, T.C., Geiss, B., Lane, K., Engle, M., Zhou, Y., Doms, R.W., Diamond,
M.S., 2005. Castanospermine, a potent inhibitor of dengue virus infection in vitro
and in vivo. J. Virol. 79 (14), 8698–8706.
Whitehead, S.S., Falgout, B., Hanley, K.A., Blaney Jr., J.E., Markoff, L., Murphy, B.R., 2003. A
live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide
deletion in the 3′ untranslated region is highly attenuated and immunogenic in
monkeys. J. Virol. 77 (2), 1653–1657.
Whitehead, S.S., Blaney, J.E., Durbin, A.P., Murphy, B.R., 2007. Prospects for a dengue
virus vaccine. Nat. Rev. Microbiol. 5 (7), 518–528.
WHO, 1997. Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and
Control, Geneva.
Yoshii, K., Hayasaka, D., Goto, A., Kawakami, K., Kariwa, H., Takashima, I., 2005.
Packaging the replicon RNA of the Far-Eastern subtype of tick-borne encephalitis
virus into single-round infectious particles: development of a heterologous gene
delivery system. Vaccine 23 (30), 3946–3956.
Yoshii, K., Goto, A., Kawakami, K., Kariwa, H., Takashima, I., 2008. Construction
and application of chimeric virus-like particles of tick-borne encephalitis
virus and mosquito-borne Japanese encephalitis virus. J. Gen. Virol. 89 (Pt 1),
200–211.
